Intensity Therapeutics (INTS), with a ~$13M market cap, closed up nearly 395% Thursday after publishing phase 1/2 results on ...
A multi-institutional team of researchers led by Case Western Reserve University has identified a pattern of clustered genetic changes that appear to encourage growth of colorectal cancer tumors—a ...
News-Medical.Net on MSN
Discovery of H2BNTac drives prostate tumor growth
Prostate cancer relies on genetic "switches", called enhancers, that can turn on tumor-promoting genes.
Northwestern Medicine scientists have discovered how a specific transcription factor promotes genetic reprogramming and ...
Prostate cancer relies on genetic "switches", called enhancers, that can turn on tumor-promoting genes.Researchers at the University of Michigan ...
The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor ...
Findings presented at European Society for Medical Oncology include models in solid tumors and hematologic malignanciesSOUTH ...
Presented at ASCO 2021 by Dr. de Bono, gumelutamide (TAS3681) is a third generation androgen receptor antagonist targeting the ligand binding domain, but this agent also had minimal activity based on ...
Intensity Therapeutics Inc. advanced stock charts by Barron's. View INTS historical stock data and compare to other stocks, and exchanges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback